Syndax Pharmaceuticals/$SNDX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Syndax Pharmaceuticals
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
Ticker
$SNDX
Sector
Primary listing
Employees
270
Headquarters
Website
SNDX Metrics
BasicAdvanced
$1.4B
-
-$3.60
0.52
-
Price and volume
Market cap
$1.4B
Beta
0.52
52-week high
$21.55
52-week low
$8.58
Average daily volume
3.2M
Financial strength
Current ratio
4.64
Quick ratio
4.355
Long term debt to equity
279.109
Total debt to equity
299.256
Interest coverage (TTM)
-10.58%
Profitability
EBITDA (TTM)
-306.898
Gross margin (TTM)
-119.70%
Net profit margin (TTM)
-279.93%
Operating margin (TTM)
-275.73%
Revenue per employee (TTM)
$410,000
Management effectiveness
Return on assets (TTM)
-39.24%
Return on equity (TTM)
-129.32%
Valuation
Price to revenue (TTM)
12.222
Price to book
11.84
Price to tangible book (TTM)
11.84
Price to free cash flow (TTM)
-4.374
Free cash flow yield (TTM)
-22.86%
Free cash flow per share (TTM)
-3.594
Growth
Revenue change (TTM)
595.65%
Earnings per share change (TTM)
-0.59%
3-year revenue growth (CAGR)
-4.20%
10-year revenue growth (CAGR)
79.42%
3-year earnings per share growth (CAGR)
145.67%
10-year earnings per share growth (CAGR)
-45.69%
What the Analysts think about SNDX
Analyst ratings (Buy, Hold, Sell) for Syndax Pharmaceuticals stock.
Bulls say / Bears say
Revuforj® delivered $28.6 million in net revenue for Q2 2025, marking a 43% jump from Q1 2025 and demonstrating strong early commercial uptake (GlobeNewswire).
The FDA granted Priority Review to Syndax's supplemental NDA for Revuforj in relapsed/refractory mNPM1 AML, with a PDUFA action date of October 25, 2025, setting up an important near-term regulatory catalyst (GlobeNewswire).
Total revenue in Q3 2025 climbed to $45.9 million, up 21% from Q2, fueled by $32.0 million in Revuforj sales and $13.9 million from Niktimvo collaboration revenue, showing increasing commercial momentum across products (GlobeNewswire).
Cash, cash equivalents, and investments dropped to $456.1 million as of September 30, 2025, from $602.1 million on March 31, 2025, reflecting significant cash burn (GlobeNewswire).
Syndax posted a net loss attributable to common stockholders of $71.8 million in Q2 2025, highlighting high operating expenses during commercial launches (GlobeNewswire).
Enrollment for the Phase 2 MAXPIRe trial of axatilimab in idiopathic pulmonary fibrosis is scheduled for completion in Q4 2025, with topline results expected only in H2 2026, pointing to a long wait for pipeline catalysts (GlobeNewswire).
Data summarised monthly by Lightyear AI. Last updated on 5 Nov 2025.
SNDX Financial Performance
Revenues and expenses
SNDX Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Syndax Pharmaceuticals stock?
Syndax Pharmaceuticals (SNDX) has a market cap of $1.4B as of November 11, 2025.
What is the P/E ratio for Syndax Pharmaceuticals stock?
The price to earnings (P/E) ratio for Syndax Pharmaceuticals (SNDX) stock is 0 as of November 11, 2025.
Does Syndax Pharmaceuticals stock pay dividends?
No, Syndax Pharmaceuticals (SNDX) stock does not pay dividends to its shareholders as of November 11, 2025.
When is the next Syndax Pharmaceuticals dividend payment date?
Syndax Pharmaceuticals (SNDX) stock does not pay dividends to its shareholders.
What is the beta indicator for Syndax Pharmaceuticals?
Syndax Pharmaceuticals (SNDX) has a beta rating of 0.52. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.